GSK 3050002
Alternative Names: Anti-CCL20 monoclonal antibody; E 6071; GSK-3050002; KANAb-071Latest Information Update: 28 Jul 2023
At a glance
- Originator GlaxoSmithKline; KAN Research Institute
- Developer GlaxoSmithKline; Morphotek
- Class Monoclonal antibodies
- Mechanism of Action CC chemokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psoriatic arthritis; Ulcerative colitis
Most Recent Events
- 31 Aug 2018 GlaxoSmithKline terminates a phase I trial for Psoriatic arthritis in Spain, Romania, Belgium and United Kingdom (NCT02671188)
- 15 May 2018 Discontinued - Phase-I for Psoriatic arthritis in United Kingdom (IV) (Eisai pipeline, May 2018)
- 15 May 2018 Discontinued - Phase-I for Ulcerative colitis in United Kingdom (IV) (Eisai pipeline, May 2018)